Literature DB >> 33492448

miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis.

Fanyi Meng1, Man Yang1, Yinshuang Chen1, Weichang Chen2,3, Weipeng Wang4.   

Abstract

Although a number of studies have revealed the important roles of miR-34a in cancer, the regulatory roles of miR-34a in cancer immune response remain largely unknown. Our present study demonstrated a mechanism underlying miR-34a-mediated cancer immune evasion via a SIRT1/NF-κB/B7-H3/TNF-α axis. miR-34a upregulated B7-H3, an important immune checkpoint molecule, through direct inhibition of SIRT1 and consequent acetylation of NF-κB subunit p65 (a-p65), which promoted B7-H3 transcription by direct binding to its promoter. The elevated B7-H3 induced production of pro-inflammatory cytokines including TNF-α. This was further confirmed in the colon of Mir34a-deficient mice, where Sirt1 expression was boosted, and the expressions of a-p65, B7h3, and Tnf were repressed. Consequently, the in vivo inhibitory activity of miR-34a on colorectal cancer (CRC) was eradicated by the reinforced B7-H3 and TNF-α. In conclusion, our study uncovered an etiological mechanism underlying miR-34a-mediated CRC immune evasion through inhibition of SIRT1 and promotion of NF-κB/B7-H3/TNF-α axis.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  B7-H3; Colorectal cancer; Immune evasion; miR-34a

Mesh:

Substances:

Year:  2021        PMID: 33492448     DOI: 10.1007/s00262-021-02862-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  43 in total

Review 1.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

2.  Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.

Authors:  Wei-Peng Wang; Pui Yan Ho; Qiu-Xia Chen; Balasubrahmanyam Addepalli; Patrick A Limbach; Mei-Mei Li; Wen-Juan Wu; Joseph L Jilek; Jing-Xin Qiu; Hong-Jian Zhang; Tianhong Li; Theodore Wun; Ralph DeVere White; Kit S Lam; Ai-Ming Yu
Journal:  J Pharmacol Exp Ther       Date:  2015-05-28       Impact factor: 4.030

3.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.

Authors:  Xi Wang; Jinge Li; Ke Dong; Fang Lin; Min Long; Yongri Ouyang; Junxia Wei; Xi Chen; Yuanyuan Weng; Ting He; Huizhong Zhang
Journal:  Cell Signal       Date:  2014-12-10       Impact factor: 4.315

5.  A microRNA component of the p53 tumour suppressor network.

Authors:  Lin He; Xingyue He; Lee P Lim; Elisa de Stanchina; Zhenyu Xuan; Yu Liang; Wen Xue; Lars Zender; Jill Magnus; Dana Ridzon; Aimee L Jackson; Peter S Linsley; Caifu Chen; Scott W Lowe; Michele A Cleary; Gregory J Hannon
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

Review 6.  Oncomirs - microRNAs with a role in cancer.

Authors:  Aurora Esquela-Kerscher; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2006-04       Impact factor: 60.716

7.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Authors:  Dmitri Lodygin; Valery Tarasov; Alexey Epanchintsev; Carola Berking; Tatjana Knyazeva; Henrike Körner; Piotr Knyazev; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2008-08-01       Impact factor: 4.534

8.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.

Authors:  Tsung-Cheng Chang; Erik A Wentzel; Oliver A Kent; Kalyani Ramachandran; Michael Mullendore; Kwang Hyuck Lee; Georg Feldmann; Munekazu Yamakuchi; Marcella Ferlito; Charles J Lowenstein; Dan E Arking; Michael A Beer; Anirban Maitra; Joshua T Mendell
Journal:  Mol Cell       Date:  2007-05-31       Impact factor: 17.970

9.  miR-34 - a microRNA replacement therapy is headed to the clinic.

Authors:  Andreas G Bader
Journal:  Front Genet       Date:  2012-07-02       Impact factor: 4.599

10.  PDL1 Regulation by p53 via miR-34.

Authors:  Maria Angelica Cortez; Cristina Ivan; David Valdecanas; Xiaohong Wang; Heidi J Peltier; Yuping Ye; Luiz Araujo; David P Carbone; Konstantin Shilo; Dipak K Giri; Kevin Kelnar; Desiree Martin; Ritsuko Komaki; Daniel R Gomez; Sunil Krishnan; George A Calin; Andreas G Bader; James W Welsh
Journal:  J Natl Cancer Inst       Date:  2015-11-17       Impact factor: 13.506

View more
  7 in total

1.  A three-phase trans-ethnic study reveals B7-H3 expression is a significant and independent biomarker associated with colon cancer overall survival.

Authors:  Yuan Gao; Yu Xu; Meiqin Gao; Aimin Huang; Pan Chi
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 2.  Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.

Authors:  Peng Ding; Zhiqiang Ma; Dong Liu; Minghong Pan; Huizi Li; Yingtong Feng; Yimeng Zhang; Changjian Shao; Menglong Jiang; Di Lu; Jing Han; Jinliang Wang; Xiaolong Yan
Journal:  Front Immunol       Date:  2022-05-02       Impact factor: 8.786

Review 3.  MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer.

Authors:  Fangfang Yang; Guoyun Xuan; Yixin Chen; Lichao Cao; Min Zhao; Chen Wang; Erfei Chen
Journal:  Front Cell Dev Biol       Date:  2022-04-08

4.  B7‑H3 promotes the epithelial‑mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway.

Authors:  Haixiu Liao; Meng Ding; Nannan Zhou; Ying Yang; Liwen Chen
Journal:  Mol Med Rep       Date:  2022-01-14       Impact factor: 2.952

Review 5.  Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.

Authors:  QinChen Xu; Xiaoyan Liu; Ghazal Mohseni; Xiaodong Hao; Yidan Ren; Yiwei Xu; Huiru Gao; Qin Wang; Yunshan Wang
Journal:  Cancer Cell Int       Date:  2022-07-30       Impact factor: 6.429

6.  Resveratrol in the Hypothalamic Paraventricular Nucleus Attenuates Hypertension by Regulation of ROS and Neurotransmitters.

Authors:  Jie Qi; Li-Yan Fu; Kai-Li Liu; Rui-Juan Li; Jin-An Qiao; Xiao-Jing Yu; Jia-Yue Yu; Ying Li; Zhi-Peng Feng; Qiu-Yue Yi; Hong Jia; Hong-Li Gao; Hong Tan; Yu-Ming Kang
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

Review 7.  Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Authors:  Jinjin Chu; Xianzhu Fang; Zhonghou Sun; Linlin Gai; Wenqing Dai; Haibo Li; Xinyi Yan; Jinke Du; Lili Zhang; Lu Zhao; Donghua Xu; Shushan Yan
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.